Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Delayed Post-Transplant Thrombocytopenia
NCT01791101Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Sep 2013
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in Thrombocytopenia, sponsored by GIMEMA. Primary endpoint: Number of patients who achieve both a platelet count ≥ 50 x 10^9/L and have doubled their baseline platelet count at 2 months. Started Sep 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT01791101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01791101.